Jennifer M. Taylor, MD, MPH, provides a brief overview of the basic scientific concepts of cancer cell suppression with checkpoint inhibitors. She also reviews the initial clinical trials for atezolizumab and pembrolizumab, larger trials for various immunotherapies for bladder cancer, toxicity reports, and ongoing research regarding these drugs in different combinations and disease states.Read More
Jennifer M. Taylor, MD, MPH
Baylor College of Medicine
Dr. Taylor received her undergraduate education from Barnard College and Columbia University in New York, NY, her MD from University of Texas Medical School, Houston, and her MPH from Harvard TH Chan School of Public Health, Boston, MA. She also did a fellowship at Memorial Sloan Kettering Cancer Center in New York, NY. Dr. Taylor currently practices Urologic Oncology at Baylor College of Medicine and the Michael E. DeBakey VA Medical Center. She is Assistant Professor of Urology at Baylor College of Medicine, as well as the Director of Preclinical and Clinical Urology courses for medical students there. She is also a member of the Dan L. Duncan Comprehensive Cancer Center at Baylor. Dr. Taylor is involved in clinical trials in multiple GU malignancies, and has a particular research interest in bladder cancer. Dr. Taylor is heavily involved in the national medical community and is a member of the American Urological Association, the Society of Urologic Oncology, the Society of Women in Urology, and the American Society of Clinical Oncology.
Articles by Jennifer M. Taylor, MD, MPH
Posted by Jennifer M. Taylor, MD, MPH | Oct 2018
Jennifer M. Taylor, MD, MPH, discusses risk-stratification in non-muscle invasive bladder cancer (NMIBC), definitions of treatment failure in this setting, and indicated workup for suspected failure. She then reviews intravesical chemotherapy options under investigation in clinical trials for Bacillus Calmette–Guérin (BCG) unresponsive NMIBC.Read More